BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - BioCardia, Inc. has successfully closed an upsized public offering, raising $7.2 million to support its biotherapeutic development and corporate purposes [1][2]. Group 1: Offering Details - The public offering included the sale of 2,400,000 shares of common stock and warrants to purchase an additional 2,400,000 shares at a combined price of$3.00 per share [1]. - The offering was conducted under Nasdaq rules and was priced at the market [1]. - The warrants have an exercise price of $3.00 per share, are immediately exercisable, and will expire five years from the issuance date [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including advancing investigational biotherapeutic candidates and the biotherapeutic delivery partnering business [2]. Group 3: Company Overview - BioCardia, Inc. is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases [4]. - The company has two main biotherapeutic platforms: CardiAMP® autologous and CardiALLO™ allogeneic cell therapies, with three clinical stage product candidates currently in development [4].